Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

TEMPO-PH (Temporal Evolution and Multi-omic Profiles in Pulmonary Hypertension)

Award Number: R01HL188754
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/07/2026
PERIOD OF PERFORMANCE END DATE: 04/30/2030

Group Awards By:

View Award Description

TEMPO-PH (Temporal Evolution and Multi-omic Profiles in Pulmonary Hypertension) - Project Summary Right heart failure is the principal cause of morbidity and mortality in pulmonary arterial hypertension (PAH), yet there are no therapies known to promote right ventricular (RV) adaptation independent of afterload reduction. This deficit extends beyond PAH, contributing substantially to poor outcomes in common cardiopulmonary diseases such as emphysema and left heart failure. The mechanisms by which the right heart adapts – or fails to adapt – to sustained pressure overload remain poorly defined. PAH, as the paradigmatic disease of right heart failure, provides an ideal model to better understand the biologic underpinnings of RV vulnerability. Angiotensin receptor blockade (ARB) is widely used in left heart failure. Preclinical and observational data suggest that ARB therapy may also benefit the failing right heart. To rigorously test this hypothesis, the NHLBI funded REVAMP-PH (PI: Leary), a five-year randomized trial of valsartan in adults with PAH. REVAMP-PH participants have undergone deep clinical phenotyping and blood draws at baseline and 24 weeks, and the trial is nearing completion. The current proposal, TEMPO-PH (Temporal Evolution and Multi-omic Profiles in Pulmonary Hypertension), will profile REVAMP-PH participants to create a rich molecular compendium of longitudinal multi-omic and extracellular vesicle analyses that will provide mechanistic insights into how renin-angiotensin-aldosterone signaling (RAAS) modulation influences right heart failure in PAH. By combining this resource with other longitudinal PAH cohorts with available multi-omics data (REHAB- PH and Servetus), we will construct a platform based on temporal molecular signals to define the pathophysiologic dynamics of RV vulnerability. This work directly supports the NHLBI strategic vision to deepen biologic understanding of disease. We will integrate multi-omics data, extracellular vesicle characterization, and discrete clinical phenotypes. Given the burden of right heart failure across diverse diseases and the absence of effective therapies that promote adaptation, these studies address an urgent and unmet need. In the short term, our work may identify actionable consequence of targeting RAAS when repurposing these well-tolerated and inexpensive medications for patients with PAH. In the long-term, TEMPO-PH may identify targetable molecular pathways, such as those implicated in the extracellular matrix or polyamine metabolism, that sustain a pipeline of therapeutic discovery in PAH and right heart failure moving into the future.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $773,815 )
2026	2026	UNIVERSITY OF WASHINGTON	4333 BROOKLYN AVE NE	SEATTLE	WA	98195	KING	USA	Lung Diseases Research	000	1	8/11/2026	NEW	$773,815
														Subtotal = $773,815

Grand Total All Awards = $773,815

Top

All Categories

About

Search

Reports

Data Submission

Award Information

TEMPO-PH (Temporal Evolution and Multi-omic Profiles in Pulmonary Hypertension)

Award Number: R01HL188754

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/07/2026

PERIOD OF PERFORMANCE END DATE: 04/30/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer